Eli Lilly's Blockbuster Weight-Loss Drugs Propel Soaring Sales, Boosting 2026 Outlook

Eli Lilly just shattered expectations for its third-quarter 2026 financial results, posting a massive 39% surge in revenue to $24.4 billion, largely thanks to the phenomenal, unyielding demand for its diabetes drug Mounjaro and weight-loss injection Zepbound. The pharmaceutical giant is now raising its full-year revenue outlook for the third time this year to an impressive $91 billion to $92 billion, signaling a clear lead in the booming metabolic disease market. These twin blockbusters, both powered by the active ingredient tirzepatide, drove an astonishing 88% of the company's year-over-year revenue increase, with Mounjaro alone pulling in $10.7 billion and Zepbound $5.3 billion. This growth comes despite competitive pressures from rivals like Novo Nordisk Wegovy and a complex pricing landscape shaped by factors like Mounjaro inclusion on China's National Reimbursement Drug List, which led to some lower realized prices. Lilly's aggressive R&D strategy also saw significant in-process R&D charges from recent acquisitions, impacting its adjusted Earnings Per Share, even as underlying performance soared. Looking ahead, Eli Lilly is not resting on its laurels. The company recently secured U.S. FDA approvals for Mounjaro to reduce cardiovascular risk and launched Foundayo, an oral GLP-1 agonist, which, while starting slower than anticipated, represents a key strategic move into convenient pill-form treatments. With its triple incretin agonist, retatrutide, showing promising Phase 3 results and expanding Medicare coverage for obesity drugs through programs like the Medicare GLP-1 Bridge, Lilly is primed to deepen its market dominance, but will need to carefully navigate evolving regulatory and pricing dynamics, including those driven by the Inflation Reduction Act.